Researchers have conclusively identified a test for antibodies that form against a particular protein, vinculin, found in the guts of patients, many of whom suffered acute gastroenteritis at some point.
"This is a major breakthrough. It is the first test with a high specificity for IBS, likely based on a pathological mechanism of the disease," said Cedars-Sinai physician researcher Mark Pimentel, co-author of the study.
In the study, 221 patients were evaluated; some had a diagnosis of IBS, some were diagnosed with IBD and some were healthy, with no symptoms.
"Until this study, there had been no accurate biomarkers identified specifically for IBS. The new blood test has the potential to distinguish IBS from IBD and reduce the need for unnecessary testing, expense and years of suffering," said Pimentel.
Irritable Bowel Syndrome is a gastrointestinal disorder characterised by diarrhea, bloating and abdominal pain. However, millions of patients are never diagnosed correctly.
A simple blood test at the first sign of symptoms means patients who have IBS could get effective treatment sooner.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
